Stazi F, Farello P, Stazi C
I Divisione Medicina Generale, Complesso Ospedaliero San Giovanni-Addolorata, Roma.
Clin Ter. 1996 Mar;147(3):85-92.
HBV and HCV cause most of chronic hepatitis; the HDV is a co-infectious virus and it rend the help of HBV to duplicate; HAV and HEV do not induce chronic hepatitis. Etiology is not the same, without apparent reasons, in all the world and the distinction between persistent chronic hepatitis and active idiopathic chronic hepatitis is meaningless, because one can shift in the other. Diagnosis is possible using serologic tests and by determination of the DNA of the HBV and RNA of the HCV. Interferon is a good therapeutic tool either for B hepatitis than for C hepatitis in about 50% of case. On the contrary, the results obtained with liver transplantation are disappointing and those achieved with ribavirin have not been conclusive yet. The treatment with INF for more than one year and with full dosages, gives good results in about 50% of patients with hepatitis D. In the other patients it is not useful a second cycle with INF or the introduction of pure antiviral drugs alone or in association with INF.
乙肝病毒(HBV)和丙肝病毒(HCV)是导致大多数慢性肝炎的病因;丁型肝炎病毒(HDV)是一种共感染病毒,它需要借助HBV进行复制;甲型肝炎病毒(HAV)和戊型肝炎病毒(HEV)不会引发慢性肝炎。在全球范围内,病因各不相同且无明显原因,持续性慢性肝炎和活动性特发性慢性肝炎之间的区分并无意义,因为二者可相互转变。可通过血清学检测以及测定HBV的DNA和HCV的RNA进行诊断。干扰素是一种有效的治疗手段,对约50%的乙型肝炎和丙型肝炎病例有效。相反,肝移植的结果令人失望,而利巴韦林的治疗效果尚无定论。使用干扰素进行为期一年以上的全剂量治疗,对约50%的丁型肝炎患者效果良好。对于其他患者,再次使用干扰素治疗周期或单独引入纯抗病毒药物或与干扰素联合使用均无效。